FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

TORONTO, Dec. 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.

For more information on the strategic partnership and study:

https://globenewswire.com/news-release/2018/12/05/1662369/0/en/Canntab-Enters-Into-a-Binding-Term-Sheet-With-Leading-Orthopaedic-Surgeon-Dr-Don-Garbuz-M-D-for-a-Clinical-Research-Trial-of-Canntab-s-Tablets.html

For More Information Click Here